Cost and insurance coverage, not efficacy alone, ultimately determined this patient's treatment course. His account of near ...
Jessica Scales, PhD, of the Melanoma Research Alliance, reviewed clinical trial access and clinician involvement in the RARE ...
A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs ...
Mark Lebwohl, MD, describes his approach on when to start systemic therapy, access considerations, and dupilumab safety and ...
A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...
Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...
Jessica Scales, PhD, of the Melanoma Research Alliance, discussed the new RARE Registry data report and dermatologists’ role ...
One clinical trial widened a patient's time in the sun, yet fear of hidden light sources remained. The conversation also ...
Two oral trial drugs changed one patient's daily life, culminating in his first beach visit without protective gear. He and ...
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting ...
Trickett and Neita compare adalimumab, secukinumab, and bimekizumab trial data and explain how comorbidities guide biologic ...
The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results